Currently approved endocrine treatments for breast cancer include aromatase inhibitors (AIs), like letrozole, selective ER modulators (SERMs), like tamoxifen, and selective ER degraders (SERDs), like fulvestrant.208. This evidence concerns the gene ESR1 and breast carcinoma.